Overactive bladder syndrome presentations at the 31st International Urogynecological Association Annual Meeting

Vella MV, Robinson DR, Cardozo LC, et al.: Still an unreliable witness? Does clinical assessment reflect patient’s perception of the overactive bladder? [abstract 15]. Int Urogynecol J Pelvic Floor Dysfunct 2006, 17(Suppl 8):66. Kelleher CJ, Basra RK, Cortes EJ: The Bladder Self-Assessment Questionnaire (BSAQ): a new screening tool for patients with lower urinary tract symptoms [abstract 19]. Int Urogynecol J Pelvic Floor Dysfunct 2006, 17(Suppl 8):68. Miller JR, Botros SM, Sand PK, et al.: Urgency on bladder palpation as a predictor of detrusor overactivity [abstract 16]. Int Urogynecol J Pelvic Floor Dysfunct 2006, 17(Suppl 8):67. Basra R, Spiteri M, Kelleher C, Khullar V: Position of bladder sensation during filling changes according to urodynamics diagnosis [abstract 130]. Int Urogynecol J Pelvic Floor Dysfunct 2006, 17(Suppl 8):134. Rahmanou P, Rajah M, Grogono J, V Khullar V: Bladder contractility in women and urodynamic diagnosis [abstract 18]. Int Urogynecol J Pelvic Floor Dysfunct 2006, 17(Suppl 8):68. Kelleher CJ, Sand PK, Dahl N: Evaluation of quality of life and safety in a large community-base population with overactive bladder [abstract 119]. Int Urogynecol J Pelvic Floor Dysfunct 2006, 17(Suppl 8):127. del Jong M, Slieker M, Vierhout ME: Pelvic floor dysfunction and quality of life in relation to sexual activity and satisfaction [abstract 20]. Int Urogynecol J Pelvic Floor Dysfunct 2006, 17(Suppl 8):69. Zahariou A, Georgantzis D, Karagiannis G, et al.: Sexuality alterations in women with urgency or urge incontinence [abstract 121]. Int Urogynecol J Pelvic Floor Dysfunct 2006, 17(Suppl 8):129. Sand PK, Kelleher CJ, Pizzi L, Dahl N: Effect of treatment for overactive bladder on work productivity [abstract 114]. Int Urogynecol J Pelvic Floor Dysfunct 2006, 17(Suppl 8):125. Sand PK, Kelleher CJ, Dahl N: Nocturia in a large community population treated with transdermal oxbutynin [abstract 116]. Int Urogynecol J Pelvic Floor Dysfunct 2006, 17(Suppl 8):126. Chapple C, Breza J, Halaska M, et al.: Patients treated with solifenacin exhibited greater reductions in incontinence episodes and pad use than tolerodine ER prior to a dose increase option in a randomized double-blind overactive bladder trial (the STAR study) [abstract 50]. Int Urogynecol J Pelvic Floor Dysfunct 2006, 17(Suppl 8):87. Chapple C, Everaert K, Madsen M, et al.: Treatment outcomes in the STAR study for patients self selecting to remain on original dose: comparison of solifenacin 5 MG and tolterodine ER 4 MG [abstract 51]. Int Urogynecol J Pelvic Floor Dysfunct 2006, 17(Suppl 8):88. Cardozo L, Nagy G, Kiss L, et al.: Solifenacin in the treatment of urgency symptoms of overactive bladder in a flexible dose, placebo controlled trial (the SUNRISE study) [abstract 52]. Int Urogynecol J Pelvic Floor Dysfunct 2006, 17(Suppl 8):88. Glavind K, Hill S, Kawakami F, K L’Heritier L: Efficacy and tolerability of darifenacin in female patients with overactive bladder (OAB): a 2-year, open-label extension study [abstract 117]. Int Urogynecol J Pelvic Floor Dysfunct 2006, 17(Suppl 8):127. Olshansky B, Foote J, Arguinzoniz M, et al.: Cardiovascular safety of darifenacin and tolterodine in patients with overactive bladder (OAB) [abstract 49]. Int Urogynecol J Pelvic Floor Dysfunct 2006, 17(Suppl 8):86. Aguirre OA: Acute pudendal nerve stimulation improves cystometric volumes in urge incontinent patients [abstract 113]. Int Urogynecol J Pelvic Floor Dysfunct 2006, 17(Suppl 8):125. Karsenty G, Elzayat E, St. Denis B, et al.: Safety of Botulinum toxin type A (BTA) injections in the trigone to treat overactive bladder (OAB): a pilot study [abstract 124]. Int Urogynecol J Pelvic Floor Dysfunct 2006, 17(Suppl 8):131. Salvatore S, Serati M, Zanfra M, et al.: Efficacy of anti muscarinics in women with anterior vaginal wall prolapse: is it the same? [abstract 115]. Int Urogynecol J Pelvic Floor Dysfunct 2006, 17(Suppl 8):126. Digesu GA, Benatti C, Maruccia S, et al.: Do overactive bladder symptoms improve after anterior vaginal wall prolapse repair? [abstract 149]. Int Urogynecol J Pelvic Floor Dysfunct 2006, 17(Suppl 8):144.